TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3343-4
Abstract: PurposeThis phase I trial evaluated the safety, pharmacokinetic profile, and antitumor activity of investigational oral TORC1/2 inhibitor TAK-228 plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.MethodsSixty-seven patients received TAK-228 6–40 mg via three dosing… read more here.
Keywords: plus paclitaxel; tak 228; trastuzumab patients; without trastuzumab ... See more keywords
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Sign Up to like & getrecommendations! Published in 2022 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01276-4
Abstract: A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced… read more here.
Keywords: second line; plus paclitaxel; ramucirumab plus; treatment ... See more keywords
Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00979-3
Abstract: Background and Objective Gastric cancer has been associated with notable geographic heterogeneity in previous multi-regional studies. In particular, patients from Japan have better outcomes compared with patients from other regions. Here, we assess patient-focused outcomes… read more here.
Keywords: plus paclitaxel; gastric cancer; japan; cancer ... See more keywords
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2016.09.024
Abstract: AIM MERiDiAN evaluated plasma vascular endothelial growth factor-A (pVEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in metastatic breast cancer (mBC). METHODS In this double-blind placebo-controlled randomised phase III trial, eligible patients had HER2-negative… read more here.
Keywords: plus paclitaxel; bevacizumab; placebo controlled; pvegf ... See more keywords
P1-347Actual clinical use of Ramucirumab plus Paclitaxel at our hospital
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx621.038
Abstract: Results: The median follow-up was 13.7 months (range: 3.1-25.2 months). The median age was 70 years (range: 56-82 years), and 5 patients were male. The primary sites of mucosal malignant melanoma were head and neck… read more here.
Keywords: plus paclitaxel; clinical use; 347actual clinical; use ramucirumab ... See more keywords
Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13806
Abstract: Apatinib, an oral antiangiogenic drug, exerts potential anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to paclitaxel monotherapy in PROC patients. read more here.
Keywords: recurrent ovarian; platinum resistant; ovarian cancer; apatinib plus ... See more keywords
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-4021
Abstract: Abstract Purpose: To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: In the double-blind, phase III BRIGHTER… read more here.
Keywords: advanced gastric; gastroesophageal junction; placebo; plus paclitaxel ... See more keywords
Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Oncology Research and Treatment"
DOI: 10.1159/000505932
Abstract: Background: The aim of the current study was to estimate two protocols for HER2-negative locally recurrent or metastatic breast cancer patients, bevacizumab combined with paclitaxel versus bevacizumab combined with capecitabine, from the economic view. Methods:… read more here.
Keywords: plus paclitaxel; bevacizumab; analysis; her2 negative ... See more keywords
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Oncology"
DOI: 10.1159/000510446
Abstract: Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT with cisplatin plus… read more here.
Keywords: plus paclitaxel; esophageal gastroesophageal; chemoradiotherapy; gastroesophageal junction ... See more keywords
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211042812
Abstract: Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study… read more here.
Keywords: plus paclitaxel; real world; line; treatment ... See more keywords
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "AntiCancer Research"
DOI: 10.21873/anticanres.15395
Abstract: Background/Aim: This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma… read more here.
Keywords: plus paclitaxel; weekly cetuximab; recurrent metastatic; oral squamous ... See more keywords